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Summary 
Background and purpose: Phytocannabinoids in Cannabis sativa have diverse 
pharmacological targets extending beyond cannabinoid receptors and several exert notable 
anticonvulsant effects. For the first time, we investigated the anticonvulsant profile of the 
phytocannabinoid cannabidivarin (CBDV) in vitro and in in vivo seizure models. 
Experimental approach: The effect of CBDV (1-100µM) on epileptiform local field 
potentials (LFPs) induced in rat hippocampal brain slices by 4-AP application or Mg2+-free 
conditions was assessed by in vitro multi-electrode array recordings. Additionally, the 
anticonvulsant profile of CBDV (50-200 mg kg-1) in vivo was investigated in four rodent 
seizure models: maximal electroshock (mES) and audiogenic seizures in mice, and 
pentylenetetrazole (PTZ) and pilocarpine-induced seizures in rat. CBDV effects in 
combination with commonly-used antiepileptic drugs were investigated in rat seizures. 
Finally, the motor side effect profile of CBDV was investigated using static beam and grip-
strength assays.  
Key results: CDBV significantly attenuated status epilepticus-like epileptiform LFPs 
induced by 4-AP and Mg2+-free conditions. CBDV had significant anticonvulsant effects in 
mES (≥100 mg kg-1), audiogenic (≥50 mg kg-1) and PTZ-induced seizures (≥100 mg kg-1). 
CBDV alone had no effect against pilocarpine-induced seizures, but significantly attenuated 
these seizures when administered with valproate or phenobarbital at 200 mg kg-1 CBDV. 
CBDV had no effect on motor function.  
Conclusions and Implications: These results indicate that CBDV is an effective 
anticonvulsant across a broad range of seizure models, does not significantly affect normal 
motor function and therefore merits further investigation in chronic epilepsy models to justify 
human trials. 
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Abbreviations: 
AED: antiepileptic drugs; 4-AP: 4-aminopyridine; CBD: cannabidiol; CBDV: 
cannabidivarin; DG: dentate gyrus; LFP: local field potential; MEA: multi-electrode 
array; mES: maximal electroshock; PTZ: pentylenetetrazole; ∆9-THC: ∆9-
tetrahydrocannabinol; TRP: transient receptor potential. 
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Introduction 
Epilepsy is a central nervous system disorder affecting ~1% of the global population, 
and is symptomatically characterised by chronic, recurrent seizures. A range of treatments are 
available, although the need for more effective and better tolerated antiepileptic drugs 
(AEDs) remains, as dictated by the pharmacological intractability of ~30% of cases and the 
poor side effect profile of currently available AEDs (Kwan et al., 2007). Cannabis sativa has 
a long history of use for control of human seizures (Mechoulam, 1986; O'Shaughnessy, 
1840), and is legally used for this indication in some countries (Sirven et al., 2004).  
 There are >100 phytocannabinoids present in Cannabis sativa, of which ∆9-
tetrahydrocannabinol (∆9-THC) is the most abundant (Elsohly et al., 2005; Mehmedic et al., 
2010) and is responsible for the classical psychoactive effects of cannabis via partial agonism 
of the CB1 cannabinoid receptor (Pertwee, 2008). Although CB1 cannabinoid receptor 
agonism can exert anticonvulsant effects in in vitro and in vivo models (Chesher et al., 1974; 
Deshpande et al., 2007; Wallace et al., 2003; Wallace et al., 2001), the most promising non-
psychoactive anticonvulsant phytocannabinoid investigated to date is cannabidiol (CBD) 
which exerts anticonvulsant actions via as yet unknown, non-CB1 cannabinoid receptor 
mechanism(s) in vitro, in vivo and in humans (Consroe et al., 1982; Cunha et al., 1980; Jones 
et al., 2010; Wallace et al., 2001); CBD’s notable anticonvulsant properties led us to 
investigate the anticonvulsant potential of its propyl analogue, cannabidivarin (CBDV). 
 CBDV was first isolated in 1969 (Vollner et al., 1969). Presently, little is known 
about the pharmacological properties of CBDV (Izzo et al., 2009), although Scutt & 
Williamson reported that CBDV can act via CB2 cannabinoid receptor-dependent 
mechanisms (Scutt et al., 2007). More recently, De Petrocellis and co-workers reported 
differential CBDV effects at transient receptor potential (TRP) channels in vitro, where it A
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acted as a human TRPA1, TRPV1 and TRPV2 agonist (EC50 values: 0.42, 3.6 and 7.3µM 
respectively) and a TRPM8 antagonist (IC50: 0.90 µM) (De Petrocellis et al., 2011a; De 
Petrocellis et al., 2011b). Additionally, CBDV inhibited diacylglycerol lipase α (IC50 
16.6µM) in vitro (De Petrocellis et al., 2011a), the primary synthetic enzyme of the 
endocannabinoid, 2-arachidonoylglycerol (Bisogno et al., 2003). Whilst the pharmacological 
relevance of these effects remains unconfirmed in vivo, they further illustrate the diversity of 
non-∆9-THC phytocannabinoid pharmacology and underline the emergent role of multiple 
non-CBR targets (Hill et al., 2012; Pertwee, 2010).  
 Here, we identify anticonvulsant effects of CBDV for the first time; thus, CBDV 
suppressed in vitro epileptiform activity in brain slices and acted as an anticonvulsant in vivo, 
normal motor function was not significantly affected by CBDV. Further investigation into 
the clinical development of CBDV as a novel AED is therefore warranted.   
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Methods 
In vitro electrophysiology 
Tissue preparation 
All experiments were carried out in accordance with Home Office regulations (Animals 
(Scientific Procedures) Act, 1986). Transverse hippocampal slices (~450µm thick) for 
multielectrode array (MEA) recordings were prepared from female and male adult Wistar 
Kyoto rats (P>21; Harlan, UK) using a Vibroslice 725M (Campden Instruments Ltd., UK) as 
previously described (Jones et al., 2010). 
 
MEA recordings 
MEA recordings and analyses were conducted as described in Hill et al. (2010). Once 
established (by addition of either 100µM 4-AP or omission of MgSO4.7H2O without 
substitution), epileptiform activity was permitted to continue for 30 min (control bursting) 
before sequential addition of 1, 10 and 100µM CBDV (30 min each). Epileptiform activity 
was characterised by spontaneous LFPs (local field potentials) recorded simultaneously 
from 59 electrodes covering the majority of the hippocampal slice preparation. The 
amplitude and duration of epileptiform LFPs was analysed for each electrode, where 
data from individual electrodes chosen based on their position in each hippocampal 
subregion were pooled to provide mean results for each subregion across n≥5 slices 
from n≥5 animals per model. Matlab 6.5 and 7.0.4 (Mathworks, Natick, Massachusetts 
USA), Microsoft Excel (Microsoft, Redmond, USA), MC_DataTool and MC_Rack (Multi 
Channel Systems GmbH) were used to process and present data as described in Hill et al. 
(2010). Inherent changes in LFP amplitude and frequency were corrected for as described in 
(Hill et al., 2010). For reference, the extent of amplitude rundown correction applied is 
illustrated in Figs. 1C and D. LFP frequency was calculated per slice (n≥5 for each model) A
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and represents the number of LFP bursts/unit time. Examples of single bursts from 
each model can be seen in Figs. 1A and B. Drug-induced changes in burst duration, 
amplitude and frequency were expressed as normalised proportions of control values ± 
S.E.M., corrected where necessary, and were analysed by Wilcoxon paired test with Holm’s 
sequential Bonferroni correction. 
 
In vivo seizure models 
Animals 
In all cases prior to seizure induction, animals were maintained on a 12:12 hour light/dark 
cycle with free access to food and water (with the exception of rats that received oral CBDV, 
see below). Audiogenic seizure experiments with DBA/2 mice (3-4 weeks old; Elevage 
Janvier, Le Genest-Saint-Isle, France) were performed at Porsolt Research Laboratory (Le 
Genest-Saint-Isle, France) in accordance with French legislation and under licence from the 
French Ministry for Agriculture and Fisheries. mES experiments with ICR (CD-1) mice (5 
weeks old; SLC Japan Inc., Japan) were performed at Otsuka Pharmaceuticals Co, Ltd, Japan 
in accordance with the guidelines of the Physiological Society of Japan. Seizure studies in 
male Wistar Kyoto rats (Harlan, UK, 3-4 weeks old) were performed at the University Of 
Reading, UK; all experiments were carried out in accordance with UK Home Office 
regulations (Animals (Scientific Procedures) Act 1986).  
 
CBDV administration 
CBDV (50, 100 or 200 mg kg-1; GW Pharmaceuticals Ltd., Salisbury, UK) was administered 
by intra-peritoneal (I.P.) injection one hour before seizure induction in all models except 
mES (30 min) in an ethanol:Cremophor:0.9%w/v NaCl vehicle (2:1:17; all Sigma, Poole, UK). 
All experiments included a control group that received volume-matched vehicle, against A
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which other groups were assessed. In mice experiments, n=10/group; in rat, n=15/group. In 
experiments where CBDV was administered orally (gavage), 400 mg kg-1 CBDV or volume-
matched vehicle (20% solutol (Sigma) in 0.9%w/v NaCl) was administered after 13.5 hours of 
fasting and 3.5 hours before I.P. administration of PTZ, n=15 for both groups (see 
supplementary methods for details on oral dose levels). 
 
Seizure induction 
mES seizures were induced in mice by a stimulator (Ugo Basile ECT, Italy) via earlap clamps 
at a current of 30 mA delivered at 100 Hz for 200 ms. DBA/2 mice were placed in a Plexiglas 
jar one hour after CBDV/vehicle administration. A mounted bell (110-120 dB) was activated 
until occurrence of a tonic audiogenic seizure or for a maximum of 60s. 85 mg kg-1 PTZ was 
injected I.P. to induce generalised seizures in rats. Status epilepticus with a temporal lobe 
focus was induced in rats by 380 mg kg-1 I.P. pilocarpine hydrochloride (Sigma; in 0.9%w/v 
NaCl), 45 min prior to pilocarpine, 1 mg kg-1 methyl scopolamine (in 0.9% w/v NaCl; Sigma) 
was administered I.P. to block peripheral effects of pilocarpine. 
 
Seizure analysis  
In mES experiments, mice were observed for 10 s during electroshock, tonic hindlimb 
extension occurrence was noted and expressed as a percentage of the total number of animals 
for each group. Audiogenic seizure behaviour was observed visually, whilst rat seizures were 
video recorded (Farrimond et al., 2009). For audiogenic seizures the incidence (as a 
percentage) of the most severe (tonic-clonic) seizures, mortality and seizure-free animals 
were calculated for each group. These parameters, as well as seizure duration and severity, 
were also determined for rat seizures. Rat behaviour was coded blind offline using The A
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Observer Pro software (Noldus, Wageningen, The Netherlands) and seizure severity scales 
appropriate to each seizure type (Table 1). Values are expressed as mean ± S.E.M throughout. 
 
Co-administration experiments 
The effect of co-administration of clinically-used AEDs with 200 mg kg-1 CBDV on PTZ- 
and pilocarpine-induced seizures was investigated. For details see supplementary methods. 
Briefly, in each experiment an AED was administered IP at either ~20, ~40 or ~70% maximal 
effective dose in the absence or presence of 200 mg kg-1 CBDV (n=15/group, 
120/experiment), convulsant (PTZ or pilocarpine) was administered one hour after CBDV or 
its vehicle. Experimental design is illustrated and summarised in Table 2. In the PTZ model, 
CBDV was co-administered with valproate or ethosuximide prior to PTZ, and with 
valproate or phenobarbital prior to pilocarpine. These AEDs were chosen based on 
their clinical profile and their reported efficacy in the models used here, with valproate 
suppressing both seizure types and ethosuximide and phenobarbital suppressing PTZ 
and pilocarpine respectively (Lindekens et al., 2000; Loscher, 2011; Loscher et al., 1991; 
Shantilal et al., 1999; Sofia et al., 1993). In co-administration experiments, seven (2.9%) 
rats exhibited a fatal reaction to CBDV administration. Behaviourally this manifested as rapid 
development (within 300 s) of lethargic convulsive movements followed by death. Overall 
this effect was seen in 2.6% of all rats that received 200 mg kg-1 CBDV across all PTZ and 
pilocarpine experiments, and not at all in side effect tests. No adverse effects of other CBDV 
doses were observed in rats, and none at any dose in mice. These animals were omitted from 
all analyses. 
 
Statistics A
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In experiments where I.P. CBDV alone was administered, the effects of CBDV on seizure 
severity, onset latency and seizure duration were assessed by one-way (ANOVA) with post 
hoc Tukey tests as appropriate. Chi squared tests followed by post hoc Fisher's exact tests 
were used where appropriate to assess differences in incidence parameters. Where CBDV 
was co-administered with an AED, two-way ANOVA or log-linear modelling was used to 
analyse the effects of CBDV and AEDs. Log-linear modelling was used to model the 
interactions between drug co-administration and incidence parameters (e.g. mortality, 
% seizure-free). If the model indicated a significant effect of drug treatment, further 
analysis to determine the contribution of CBDV, the relevant AED and any drug x drug 
interaction was performed; these analyses are given in the text and in Supplementary 
Tables 1 and 2.  
 
Motor function assays 
The effects of CBDV (50, 100 and 200 mg kg-1) and valproate (125, 250 and 350 mg kg-1) on 
normal rat motor function were assessed on a 1 m raised static beam and by a grip strength 
test (see Supplementary Methods for details).  
 
All receptor an ion channel nomenclature conforms to Alexander et al., 2011.  
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Results 
Effects of pure CBDV in the Mg2+-free and 4-AP models of in vitro epileptiform activity 
 The effects of CBDV (1-100 µM) on epileptiform activity in rat acute hippocampal 
slices induced by Mg2+-free aCSF (Fig. 1A) or 100 µM 4-AP (Fig. 1B) were examined. 
CBDV significantly decreased the amplitude and duration of epileptiform local field 
potentials (LFPs) induced by Mg2+-free aCSF (Fig. 1C&D; p≤0.05); significant effects were 
seen at ≥10 µM, and CA3 was more resistant to the effects of CBDV than DG or CA1 (Fig. 
1C&D). Conversely, CBDV significantly increased Mg2+-free-induced LFP frequency (≥10 
µM; Fig. 1E; p≤0.05).  
An anti-epileptiform effect of 100 µM CBDV on the amplitude of 4-AP-induced 
epileptiform LFPs was observed in the CA1 region alone (Fig. 1F; p≤0.05), whereas LFP 
duration was significantly lowered in all hippocampal regions by ≥10 µM CBDV (Fig. 1G) 
and, by contrast to the Mg2+-free model, 4-AP-induced LFP frequency was significantly 
decreased by all CBDV concentrations tested (Fig. 1H; p≤0.05). Thus, CBDV attenuated the 
duration of amplitude of LFPs in both models, and had differential effects on frequency.  
Effects of CBDV on maximal electroshock (mES) and audiogenic seizures in mice 
 The effects of CBDV (50-200 mg kg-1) on mES convulsions and audiogenic seizures 
in mice were investigated. CBDV had a significant anticonvulsant effect on animals 
displaying tonic hind-limb extension after mES (X2(3)=15.000; p≤0.001; Fig. 2A); 
significantly fewer animals that received 100 or 200 mg kg-1 CBDV exhibited hind-limb 
extension (both groups 30%) than those that received vehicle (90%, Fig. 2A; p≤0.001 vs. 
vehicle treated group). Audiogenic seizures were also significantly attenuated by CBDV (Fig. 
2B-D). The incidence of tonic convulsions was significantly lower after CBDV A
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administration (X2(3)=19.436, p≤0.001; Fig. 2B); 80% of vehicle-treated animals developed 
tonic convulsions compared to only 20% (50 mg kg-1 CBDV), 10% (100 mg kg-1 CBDV) and 
0% (200 mg kg-1 CBDV) after drug treatment (each p≤0.001 vs vehicle). The proportion of 
animals that remained seizure-free was significantly higher after administration of 200 mg kg-
1
 CBDV (90%) than vehicle (0%; X2(3)=27.461, p≤0.001; Fig. 2C). Finally, a statistical 
trend was observed for the mortality rate (X2(3)=6.667, p≤0.1), with lower mortality after 
100 and 200 mg kg-1 CBDV treatment than vehicle (0% vs 30% respectively; Fig. 2D). Thus, 
CBDV exhibits strong and significant anticonvulsant effects in two broad-screen mouse 
seizure models. We therefore next investigated the anticonvulsant potential of CBDV in two 
further models of seizure in rat that emulate more specific seizure types. 
Effects of CBDV on PTZ- and pilocarpine-induced seizures in rat 
 We investigated the effect of CBDV (50-200 mg kg-1) on PTZ-induced seizures. 
CBDV significantly decreased PTZ seizure severity (F3,58=4.423, p≤0.05; Fig. 3A); the 
median seizure severity after vehicle administration was tonic-clonic convulsion (score [5]), 
but after 200 mg kg-1 CBDV administration seizure severity was significantly lowered to a 
median severity of bilateral clonic convulsion (score [3]; p≤0.05). CBDV also significantly 
reduced mortality (X2(3)=10.356, p≤0.05; Fig. 3B) at 100 and 200 mg kg-1 CBDV (p≤0.01). 
The proportion of animals remaining seizure-free was significantly increased by CBDV 
administration (X2(3) =7.809, p≤0.05; Fig. 3C); 33.3% of animals that received 200 mg kg-1 
CBDV exhibited no signs of seizure, compared to only 6.7% of animals that received vehicle 
(p≤0.01). Furthermore, seizure onset was significantly delayed by CBDV treatment 
(F3,50=2.971, p≤0.05; Fig. 3D); mean onset latency was significantly longer after 
administration of 200 mg kg-1 CBDV than vehicle (65±11s and 40±4s respectively; p≤0.05). 
Thus, CBDV administered alone exhibited strong and significant anticonvulsant effects on A
cc
ep
te
d 
A
rti
cl
e
13 
© 2012 The Authors 
British Journal of Pharmacology © 2012 The British Pharmacological Society 
PTZ seizures at 200 mg kg-1 (Fig. 3A-D) with more limited, but significant, effects at 100 mg 
kg-1 (Fig. 3B). 
We extended our studies to investigate the effects of CBDV (50-200 mg kg-1) on 
the convulsions associated with pilocarpine-induced status epilepticus (380 mg kg-1). 
CBDV (50-200 mg kg-1) had no significant effect on the severity (F3,59=0.049, p>0.1; Fig. 
3E) or resultant mortality of pilocarpine convulsions (X2(3)=1.779, p>0.1; Fig. 3F). 
Similarly, CBDV did not significantly affect the proportion of animals that remained 
seizure-free (X2(3)=0.110, p>0.1; Fig. 3G) or the latency to the onset of convulsions 
(F3,53=0.404, p>0.1; Fig. 3H).  
 
Effect of co-administration of CBDV and AEDs on PTZ- and pilocarpine-induced seizures 
in rat 
 We investigated the properties of CBDV when co-administered with AEDs prior 
to PTZ or pilocarpine treatment. The effects of combined drug treatment (CBDV + 
AED) on seizure parameters are described here and illustrated in Figures 4 and 5, as is 
the contribution of CBDV to these effects. The contribution of AEDs is illustrated in 
Figures 4 and 5 while statistical analyses of AED effects and any interaction between 
CBDV and AEDs are shown in Supplementary Table 1. 
200 mg kg-1 CBDV was co-administered with valproate (50-250 mg kg-1) or 
ethosuximide (60-175 mg kg-1). In CBDV + valproate experiments, drug co-
administration had significant anticonvulsant effects on all seizure parameters except 
the proportion of animals remaining seizure-free. CBDV and valproate co-
administration significantly decreased seizure severity (F7,112=10.449, p≤0.001; Fig. 4A). A
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When modelled by log linear analyses, our data indicated that drug co-administration 
decreased mortality (Fig. 4B) and the incidence of the most severe (tonic-clonic) seizures 
(Fig. 4C). Seizure onset was significantly delayed by drug co-administration 
(F7,109=13.285, p≤0.001; Fig. 4D) and the mean duration of seizures was increased 
(F7,103=5.250, p≤0.001). Valproate contributed significantly to all these effects (Fig. 4A-
D, Supplementary Table 1). CBDV significantly contributed to the overall decrease in 
severity (F1,112=5.748, p≤0.05; Fig. 4A) and mortality (X2(1)=6.639, p≤0.01; Fig. 4B) and 
the increase in onset latency (F1,109=7.393, p≤0.01; Fig. 4C). CBDV did not significantly 
affect tonic-clonic seizure incidence (Fig. 4D) or seizure duration (p>0.1). No effect of 
drug treatment on the number of seizure-free animals was observed (X2(14)=8.930, 
p>0.1) and no significant positive or negative interactions between the effects of 200 mg 
kg-1 CBDV and valproate were observed (Supplementary Table 1; p>0.1). 
 Co-administration of 200 mg kg-1 CBDV and ethosuximide (60-175 mg kg-1) had 
significant anticonvulsant effects on all parameters of PTZ-induced seizures: CBDV 
and ethosuximide co-administration significantly decreased seizure severity 
(F7,110=12.556, p≤0.001; Fig. 4E), when modelled with log linear analysis, our data 
indicated that co-administration also decreased mortality (Fig. 4F) and the incidence of 
the most severe seizures (Fig. 4G). Seizure onset latency was significantly increased 
(F7,76=7.885, p≤0.001; Fig. 4H), as was the proportion of animals that remained seizure-
free (log linear model; Fig 4I); seizure duration was significantly decreased 
(F7,102=6.934, p≤0.001). Ethosuximide significantly contributed to all anticonvulsant 
effects (Fig. 4E-I; Supplementary Table 1). CBDV contributed significantly to the 
overall decreases in seizure severity (F1,112=7.474, p≤0.01; Fig. 4E) and mortality 
(X2(1)=5.174, p≤0.05; Fig. 4F); the contribution of CBDV to the increase in onset latency 
showed a statistical trend (F1,76=2.791, p≤0.1; Fig. 4H). CBDV did not significantly A
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contribute to the effects on seizure duration, the proportion of animals that remained 
seizure-free (both p>0.1) or the incidence of the most severe seizures (p>0.1; Fig. 4G). 
No significant positive or negative interactions between the effects of 200 mg kg-1 CBDV 
and ethosuximide were observed (Supplementary Table 1; p>0.1). 
 We next investigated whether 200 mg kg-1 CBDV affected the anticonvulsant 
actions of valproate or phenobarbital on pilocarpine-induced convulsions. Interestingly, 
these co-administration experiments highlighted significant anticonvulsant effects of 
200 mg kg-1 CBDV not previously observed when CBDV was administered alone. Co-
administration of valproate (50-250 mg kg-1) with 200 mg kg-1 CBDV had significant 
anticonvulsant effects on all parameters except the proportion of animals that remained 
convulsion-free: CBDV and valproate co-administration significantly decreased severity 
(F7,100=16.477, p≤0.001; Fig. 5A); when modelled by log linear analysis, our data 
indicated that mortality (Fig. 5B) and the incidence of the most severe (tonic-clonic) 
convulsions (Fig. 5C) were also decreased by drug co-administration; onset latency was 
significantly increased (F7,105=8.649, p≤0.001; Fig. 5D). Valproate contributed 
significantly to all anticonvulsant effects (Fig. 5A-D, Supplementary Table 2) with the 
interesting exception of mortality. Although not significantly so, mortality was higher 
after 62.5 and 125 mg kg-1 valproate were co-administered with vehicle (Fig. 5B), 
however CBDV had an anticonvulsant effect, significantly decreasing mortality 
compared to administration of its vehicle (X2(1)=4.010, p≤0.05; Fig. 5D). CBDV also 
significantly contributed to the overall anticonvulsant effects of treatment on severity 
(F1,110=22.711, p≤0.001; Fig. 5A) and the incidence of tonic-clonic convulsions 
(X2(1)=4.010, p≤0.01; Fig. 5C) although had no significant effect on onset latency (p>0.1; 
Fig. 5D). The proportion of animals that remained convulsion-free (X2(6)=1.564, p>0.1) A
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was unaffected by treatment. No significant interactions between CBDV and valproate 
effects were observed (Supplementary Table 2; p>0.1). 
 Co-administration of 200 mg kg-1CBDV and phenobarbital (10-40 mg kg-1) had 
significant anticonvulsant effects on the severity of pilocarpine-induced convulsions 
(F7,108=19.352, p≤0.001; Fig. 5E). When modelled with log linear analyses, our data 
indicated that there was no effect of treatment on mortality was observed (Fig. 5F), 
whereas the proportion of animals that developed tonic-clonic convulsions was 
significantly decreased (Fig. 5G). No effect of drug treatment was observed on seizure 
onset latency (p>0.1; Fig. 5H), however, when modelled with log linear analysis, our 
data indicated that the proportion of animals that remained convulsion-free was 
significantly increased (Fig. 5I). Phenobarbital significantly contributed to all 
anticonvulsant effects (Fig. 5E-I; Supplementary Table 2). CBDV significantly 
contributed to the overall decrease seen in severity (F1,108=4.480, p≤0.05), and the effects 
of CBDV and phenobarbital interacted significantly due to a convergence of the severity 
observed in the absence and presence of CBDV (Fig. 5F Supplementary Table 2; 
F3,108=3.105, p≤0.05), no further significant interactions between the effects of CBDV 
and phenobarbital were observed (p>0.1; Supplementary Table 2).  
Data from the co-administration experiments demonstrate that the AEDs 
strongly suppress PTZ-induced seizures and pilocarpine-induced convulsions in a dose-
dependent manner as expected (Figures 4 and 5). 200 mg kg-1 CBDV significantly 
contributed to the anticonvulsant effects observed in these experiments as assessed by 
several, but not all, parameters examined. To more precisely assess the effect of CBDV 
on AED actions in these studies, we performed pairwise comparisons at each dose of 
AED between groups which received CBDV vehicle and groups that received 200 mg A
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kg-1 CBDV; these analyses were only performed if two-way ANOVA or log linear 
analysis results indicated an overall effect of CBDV upon a given parameter. Based on 
these analyses and Figs. 5F-I, the effect of CBDV on the actions of phenobarbital in the 
pilocarpine model appears limited and is not significant. Similarly, the effect of CBDV 
on the actions of valproate in the PTZ model was limited (Figs. 4A-D); the primary 
effect of CBDV is on delaying seizure onset, as 200 mg kg-1 CBDV significantly 
improved the effect of 50 mg kg-1 valproate (p≤0.05; Fig. 4D) and showed a statistical 
trend towards the same effect at 100 mg kg-1 valproate (p<0.1). More notably, CBDV 
significantly improved the effect of 60 mg kg-1 ethosuximide on PTZ-induced seizure 
severity and onset latency (p≤0.05; Figs. 4E and H), also showing a statistical trend to 
improvement of the 120 mg kg-1 ethosuximide effect for both these measures (p<0.1). 
Furthermore, when 200 mg kg-1 CBDV was administered together with valproate prior 
to pilocarpine administration, it significantly improved the effects of valproate on 
severity (62.5 and 250 mg kg-1; p≤0.05), mortality (62.5 and 125 mg kg-1; p≤0.05) and the 
proportion of animals that experienced the most severe seizures (all doses, p≤0.01; Figs. 
5A-C).  
Thus, CBDV is well-tolerated when co-administered with AEDs and does not 
interact antagonistically with any of the AEDs studied in either seizure model. 
Furthermore, CBDV has significant anticonvulsant properties when co-administered 
with ethosuximide in the PTZ model and even greater effects when co-administered 
with valproate in the pilocarpine model where beneficial effects generally were observed 
at low and medium AED doses. CBDV had no impact on the effects of phenobarbital in 
the pilocarpine model and only very limited effects on the onset of seizures when co-
administered with valproate prior to PTZ treatment.   A
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CBDV motor side effect profile and anticonvulsant efficacy via oral administration 
 To further determine the suitability of CBDV as a clinical candidate, we assessed both 
its motor side effect profile and whether it could suppress seizures when administered orally 
prior to PTZ treatment. Many currently-used AEDs cause significant side effects at clinically 
effective doses, particularly on motor function (Schachter, 2007), whilst orally-delivered 
seizure suppression is a prerequisite for human epilepsy treatment.  
We used two motor tasks to investigate the side effect profile of CBDV (50-200 mg kg-1): a 
static beam test to assess motor coordination (Roberts et al., 2006; Stanley et al., 2005) and a 
grip-strength test to assess drug-induced muscle relaxation and functional neurotoxicity 
(Crofton et al., 1996; Nevins et al., 1993). CBDV had no significant effect on motor 
performance at any dose compared to vehicle treatment (Fig. 6A-D). In the static beam assay, 
the pass rate (X2(3)=4.053; p>0.1; Fig. 6A) and mean distance travelled (F3,79=1.335; p>0.1; 
data not shown) were both unaffected by CBDV. CBDV had no significant overall effect on 
the mean number of foot slips (F3,79=0.858; p>0.1; Fig. 6B), although we did note a non-
significant increase in foot slips in  animals treated with 200 mg kg-1 CBDV (0.70±0.25 
slips, compared to 0.30±0.11 slips after vehicle treatment). CBDV had no effect on grip 
strength (F3,79=0.465; p>0.1, Fig. 6C). To validate the tests’ ability to detect AED-induced 
motor deficits, a second group of animals received valproate (125-350 mg kg-1) or saline 
vehicle. Valproate significantly affected the proportion of animals that successfully 
completed the static beam test (X2(3)=35.084; p≤0.001; Fig. 6A), with doses ≥250 mg kg-1 
significantly decreasing the pass rate (p≤0.01). Similarly, both the number of foot slips 
(F3,78=9.140; p≤0.001; Fig. 6B) and the mean distance travelled (F3,78=15.561; p≤0.001; data 
not shown) were significantly, negatively and dose-dependently affected by treatment with A
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≥250 mg kg-1 valproate (p≤0.01). Valproate also significantly affected the grip strength of 
animals (F3,79=3.175; p≤0.05; Fig. 6C), with a small but significant decrease in mean strength 
induced by 350 mg kg-1 valproate (p≤0.05). 
 Finally, we investigated the ability of orally administered 400 mg kg-1 CBDV (see 
supplementary methods for dose details) to suppress PTZ seizures (90 mg kg-1). 400 mg kg-1 
CBDV significantly lowered the severity of PTZ-induced seizures (Fig. 6D, p≤0.05) from [5] 
to [3.5]. There were no significant effects of CBDV on seizure onset latency (vehicle 
58.6±3.7 s; CBDV 61.8±5.2 s; p>0.1), percentage mortality (vehicle 26.7%; CBDV 20%; 
p>0.1) or development of tonic-clonic seizures (vehicle 53.3; CBDV 33.3; p>0.1). Overall, 
we demonstrate that the anticonvulsant effects of CBDV in rat are due to genuine 
anticonvulsant properties and not motor suppression, and that CBDV is anticonvulsant when 
administered orally as well as I.P in the PTZ model. 
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Discussion 
 This study demonstrates the anticonvulsant properties of CBDV for the first time and 
is the only to-date that has investigated CBDV effects in whole animals. Our main finding is 
that CBDV suppresses seizures in four in vivo seizure models at doses ≥50 mg kg-1. CBDV 
also does not affect normal motor function and is well-tolerated when co-administered with 
AEDs. Moreover, CBDV suppresses epileptiform activity in vitro.  
 
In vitro effects of CBDV 
 In both in vitro models of epileptiform activity, LFP duration and amplitude were 
significantly decreased by CBDV, with efficacy varying between hippocampal subregions 
and models. CA3 was most resistant to CBDV effects, potentially due to its role as the 
epileptiform focus (Hill et al., 2010; Perreault et al., 1992). It is also reported that a smaller 
proportion of neurons in CA1 contribute to burst activity than CA3 (Perreault et al., 1992), 
potentially rendering CA1 more sensitive to anti-epileptiform drug effects. CBDV effects on 
LFP frequency in the two models were opposite; CBDV increased Mg2+-free-induced LFP 
frequency, but decreased 4-AP-induced LFP frequency. This may be due to a genuine, 
model-dependent CBDV effect on LFP frequency; however the response of frequency in 
the Mg2+-free model is in direct contrast to all other findings across both models, where 
varying degrees of anti-epileptiform effects were observed. In addition, we have 
observed that LFPs in the Mg2+-free model exhibit greater variation in frequency than 
the 4-AP model, occurring in sporadic bursts of LFPs with periods of relative 
quiescence between (see Hill et al., 2010), thus, whilst the frequency of LFPs in this 
model was corrected to allow for inherent increases, it may be that the unpredictability 
of LFP incidence limits the accuracy of this process. Overall, the magnitude of CBDV A
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effects on LFP amplitude and duration are comparable with both CBD and clinically-
used AEDs (Hill et al., 2010; Jones et al., 2010; Sagratella, 1998). 
 
In vivo effects of CBDV and clinical implications 
 CBDV possessed significant anticonvulsant properties in four seizure models with 
different bases across two species. CBDV was effective in three models of generalised 
seizure – mES and audiogenic in mice and PTZ in rat. In particular, CBDV (200 mg kg-1 
completely prevented tonic-clonic convulsions in the audiogenic seizure model and had 
robust effects in the mES model in line with the reported efficacy of valproate and other 
AEDs in these models (Gareri et al., 2004; Luszczki et al., 2011; Luszczki et al., 2012). 
Moreover, positive findings in the mES model - a primary screen for putative 
anticonvulsants (Loscher, 2011) - are predictive of clinical efficacy against generalised 
human seizures (Loscher, 2011), whilst audiogenic seizures, although providing limited 
predictive differentiation of future efficacy against human seizure types (Loscher, 2011), are 
also a useful model of generalised seizure (Pitkanen et al., 2006). As well as predicting 
effective suppression of generalised seizures in humans, attenuation of PTZ-induced seizures 
can be predictive of efficacy against absence seizures (Veliskova, 2006), thus CBDV should 
also be investigated in non-convulsive seizure models (e.g. WAG/Rjj rats (Coenen et al., 
2003)). Importantly, P.O. CBDV (400 mg kg-1) also suppressed PTZ-induced seizures, 
showing that CBDV can exert anticonvulsant effects via oral administration routes. 
Systemic administration of pilocarpine induces status epilepticus with a temporal lobe 
focus that subsequently generalises and is associated with motor convulsions (Curia et al., 
2008). Interestingly, the anticonvulsant effects of CBDV only became apparent when 200 mg 
kg-1 CBDV and AEDs were co-administered. Thus, effects were observed only in higher-
power experiments in which 60, as opposed to 15, animals received 200 mg kg-1 CBDV. A
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These effects were limited (see below), suggesting that CBDV acts less efficaciously in this 
model than in the others studied here, however our statistical analyses assert that CBDV 
effects in these experiments were independent of, and separate to, AED actions. In the future, 
it would be of interest to continue characterising CBDV effects on pilocarpine-induced 
status epilepticus using direct recordings of brain activity, for example via 
electroencephalographic or electrocorticographic recordings in this model as status 
epilepticus activity can persist in the absence of motor activity.  
Many AEDs exert significant motor side effects (Schachter, 2007) which can limit 
patient quality of life. To address this and confirm that CBDV's anticonvulsant actions were 
due to direct actions on seizures and not motor suppression, we investigated the performance 
of rats treated with CBDV in static beam and grip strength tasks. These tests assess balance, 
coordination, muscle relaxation and drug-induced functional neurotoxicity (Crofton et al., 
1996; Muller et al., 2008; Nevins et al., 1993; Stanley et al., 2005). CBDV did not affect grip 
strength, and although the number of foot slips did increase after 200 mg kg-1 CBDV 
treatment, this effect was not significant. Our tests were validated by the finding that 
valproate negatively affected all motor parameters, consistent with previous studies (Roks et 
al., 1999).  
The above in vivo results indicate that CBDV has comparatively strong anticonvulsant 
effects in a range of seizure models, has significant potential for the treatment of generalised, 
human seizures and should be further investigated against temporal lobe seizures. 
Furthermore, data from motor function assays indicate that CBDV does not cause significant 
adverse motor effects at anticonvulsant doses. Our tests were validated by the finding that 
valproate negatively affected all motor parameters, consistent with previous studies (Roks et 
al., 1999). In future, it will be of great interest to investigate CBDV’s properties in A
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models of chronic epilepsy and hyperexcitability. The impact of chronic CBDV 
treatment on behaviour in healthy and epileptic animals is also worthy of investigation.  
 
Co-administration studies 
 Clinical investigation of new anticonvulsants is typically performed using the 
candidate AED as an adjunctive treatment to the patient's current treatment regimen (French, 
2001) (French et al., 2001). Therefore, we investigated the effects of CBDV (200 mg kg-1) 
when co-administered with clinically used anticonvulsants. The three anticonvulsants used 
were chosen based on their use as prescribed AEDs and, more pragmatically, reported 
efficacy in the seizure models used (Lindekens et al., 2000; Loscher, 2011; Loscher et al., 
1991; Shantilal et al., 1999; Sofia et al., 1993). No negative interactions between CBDV 
and the AEDs were observed, indicating that CBDV is well-tolerated when co-
administered with the three clinically used AEDs employed in these studies. The 
anticonvulsant effect of CBDV beyond that of these AEDs was variable, in our study. 
When administered with ethosuximide prior to PTZ or valproate prior to pilocarpine, 
CBDV contributed significantly to the effects seen on severity (both cases), mortality 
(valproate in pilocarpine only), latency (ethosuximide only) and the incidence of tonic-
clonic convulsions (valproate in pilocarpine only). The majority of CBDV’s significant 
facilitatory effects were seen at the lower two doses, this is could due to the greater 
potential for anticonvulsant actions when the AED is not producing a maximal effect 
itself. However, 200 mg kg-1 CBDV appeared to have little effect on pilocarpine-induced 
convulsions when administered with phenobarbital at any dose, although it should be 
noted that all doses of phenobarbital strongly suppressed seizure activity, likely to limit 
CBDV’s impact. CBDV had limited effects on PTZ-induced seizures when co-
administered with valproate. Thus, CBDV had AED-dependent effects in these A
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experiments, producing notable improvements over AED treatment alone in two of four 
experiments. Based on these data, we postulate that CBDV is well-tolerated when co-
administered with three AEDs used in the clinic for a variety of epileptic syndromes, 
but that further investigation of its anticonvulsant properties in combination with other 
drugs is required, for example, using isobolographic experimental design and analysis 
(e.g. Luszczki et al., 2010). 
 
Anticonvulsant mechanisms of CBDV 
 This is the first investigation of CBDV effects in any in vivo model or system; in vitro 
information on CBDV pharmacological properties, whilst growing, is limited (De Petrocellis 
et al., 2011a; De Petrocellis et al., 2011b; Scutt et al., 2007) and remains of unknown in vivo 
or clinical relevance. For example, reported effects of CBDV at recombinant TRP channels 
are as yet unconfirmed in native tissue and it is unknown how such TRP-based mechanisms 
of action could affect excitability in epileptogenic areas. Whilst TRPV1 expression in brain 
areas including the hippocampus remain controversial (Cavanaugh et al., 2011; Mezey et al., 
2000), the functional expression of other TRP subtypes in relevant parts of the brain has yet 
to be confirmed (Crawford et al., 2009; Hirata et al., 2010). CBDV has also been reported to 
inhibit DAGLα (De Petrocellis et al., 2011a), the enzyme responsible for production of the 
endocannabinoid 2-arachidonoylglycerol (2-AG; Stella et al., 1997). The effect of 
inhibiting 2-AG production is likely to be complex. The initial effect would be to 
decrease 2-AG levels and subsequent CB1 cannabinoid receptor activation. However, 
the overall effect of this on seizure activity would depend on proportional CB1 
cannabinoid receptor expression and localisation on different presynapses (i.e. 
excitatory or inhibitory) and the contribution of inhibitory GABAergic circuits in brain 
areas crucial to epileptogenesis, as a decrease in 2-AG would result in less suppression A
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of both excitatory and inhibitory synapses. Furthermore, over longer time courses, it 
has been reported that CB1 cannabinoid receptor levels can be affected by changes in 
agonist levels i.e. higher levels of CB1 cannabinoid receptor agonist can increase 
internalisation of the receptor (Coutts et al., 2001). Thus, reduced 2-AG levels could 
cause increased CB1 cannabinoid receptor at the membrane. Additionally, whilst this 
study investigated CBDV effects only upon acute seizures, CB1 cannabinoid receptor 
expression changes during both animal models (e.g. pilocarpine-induced SRS as a model 
of temporal lobe epilepsy) of chronic epilepsy and in human epilepsy (Karlocai et al., 
2011; Magloczky et al., 2010), which could affect the consequences of changes in 
endocannabinoid levels upon seizure activity. Direct anticonvulsant action via CB1 
cannabinoid receptor agonism has been reported for ∆9-THC (Wallace et al., 2001), however 
CBDV effects at the CB1 cannabinoid receptor  remain to be characterised and, furthermore, 
200 mg kg-1 CBDV caused no significant effects in the motor function assays used here, 
whilst CB1 cannabinoid receptor agonists produce significant motor deficits (Carlini et al., 
1974), suggesting that CBDV does not act via CB1 cannabinoid receptor agonism. 
CBDV is the propyl analogue of CBD. A solely qualitative comparison of the 
effects of CBD and CBDV on PTZ-induced seizures shows that both compounds 
improve mortality and severity; CBD showing these effects at 100 mg kg-1, a dose at 
which CBDV did not affect severity. CBD showed no indication of affecting onset 
latency (≤100 mg kg-1), CBDV delayed seizure onset in a dose-dependent manner that 
reached significance at 200 mg kg-1. The comparison between CBD and CBDV in the 
pilocarpine model is less simple as CBDV at 200 mg kg-1 had wider-ranging 
anticonvulsant effects in our co-administration experiments (on severity, mortality and 
latency as well as the proportion of animals that developed tonic-clonic convulsions) but 
was not effective in initial experiments at any dose, whereas low-dose CBD affected A
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tonic-clonic convulsions but no other measures. A direct experimental comparison both 
of efficacy and how similarly CBD and CBDV affect seizures may be of interest. 
Although assumptions of pharmacological similarity on the basis of structural 
homology should be made with caution (e.g. the opposing effects of ∆9-THC and ∆9-
THCV on CB1 cannabinoid receptors), CBD is anticonvulsant in animals and humans 
and more is known about CBD’s pharmacological properties, if not its specific 
anticonvulsant mechanism(s) of action. CBD is unlikely to act via CB1 cannabinoid 
receptor, but has a wide range of known pharmacological targets that could underlie its 
anticonvulsant effects (Hill et al., 2012). These include inhibition of T-type Ca2+ 
channels (Ross et al., 2008), inhibition of GPR55 in some tissues/preparations (Ryberg et 
al., 2007), modulation of mitochondrial calcium handling in neurons (Ryan et al., 2009) 
and increased activity of inhibitory non-cannabinoid G protein-coupled receptors 
including 5-HT1A (direct agonism; (Russo et al., 2005)) and adenosine A1 (via effects on 
adenosine uptake;(Carrier et al., 2006)). Thus, if CBDV shares some or all of CBD’s 
pharmacological targets, it is possible that CBDV also acts via multiple mechanisms to 
produce its overall anticonvulsant effect, as opposed to exerting a high-efficacy action at 
a single target. However, there is no a priori reason to assume a common target and 
there is clearly some divergence between CBD and CBDV properties, for example CBD, 
but not CBDV, inhibits FAAH (De Petrocellis et al., 2011a). 
In conclusion, our most important finding is that CBDV possesses strong 
anticonvulsant properties in a range of in vivo seizure models that parallel a variety of 
human seizure types and pathologies; anticonvulsant effects were also seen after oral, as well 
as I.P., administration. As with many clinically-used AEDs, further work is required to 
determine the anticonvulsant mechanism of CBDV, but the significant anticonvulsant 
effects and favourable motor side effect profile demonstrated in this study identify A
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CBDV as a potential standalone AED or as a clinically useful adjunctive treatment 
alongside other AEDs. 
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Figure 1. Effects of CBDV on hippocampal epileptiform activity  
A & B: Example traces showing effects of 100 µM CBDV on epileptiform LFPs induced by 
Mg2+-free conditions (A) or 100 µM 4-AP (B) in the CA1 region. The black bar represents 
amplitude as corrected for inherent rundown (see Methods); the dotted line below represents 
control burst duration. Scale in A: 100µV/200 ms; B: 150µV/200 ms. C-H: Effects of CBDV 
on amplitude (C&F), duration (D&G) and frequency (E&H) of epileptiform LFPs induced 
by Mg2+-free conditions (C-E) or 100 µM 4-AP (F-H). Data is presented as mean ± S.E.M. 
normalised to control (pre-drug) conditions and corrected for background changes where 
appropriate (see Methods). LFP amplitude and duration values are expressed for each 
hippocampal region as in the key. n=9-12. *= p≤0.05, **= p≤0.01 and ***= p≤0.001. 
 
Figure 2. Effects of CBDV on mES and audiogenic seizures in mice 
A: The effect of CBDV on the percentage of animals that exhibited tonic hindlimb extension 
in response to mES. B-D: The effect of CBDV (50-200 mg kg-1) on the percentage of animals 
that displayed tonic convulsions (B), remained seizure-free (C) or suffered mortality (D) as a 
result of audiogenic seizure induction. n=10 in all cases, *** = p≤0.001. 
 
Figure 3. Effects of CBDV on PTZ- and pilocarpine-induced seizures in rat 
A-D: The effect of CBDV on PTZ-induced seizures: seizure severity (A), mortality (B), the 
proportion of animals remaining seizure-free (C) and the onset latency (D). E-H: The effect 
of CBDV on pilocarpine-induced convulsions: severity (E), mortality (F), the proportion of 
animals remaining seizure-free (G) and the onset latency (H). In D & H, onset latency is 
presented ± S.E.M. In A & E median severity is represented by a thick horizontal line, the A
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25th & 75th percentiles by the box and maxima and minima are represented by "whiskers". 
n=15 in all cases. *= p≤0.05, **= p≤0.01 and ***= p≤0.001. 
 
Figure 4. Effects of co-administration of CBDV and AEDs on PTZ-induced seizures in 
rat 
The effects of CBDV co-administration with valproate (A-D) or ethosuximide (E-I) on PTZ 
induced seizures: severity (A & E), mortality (B & F), the incidence of tonic-clonic seizures 
(C & G), onset latency (D & H) and (for CBDV+ethosuximide only) the proportion of 
animals that remained seizure-free. In D & H, onset latency is presented ± S.E.M. In A & E, 
median severity is represented by a thick horizontal line, the 25th & 75th percentiles by the 
box and maxima and minima are represented by "whiskers". Co-administration of 200 mg kg-
1
 CBDV is represented by grey plots, CBDV vehicle by black. Significance of CBDV 
treatment is given in text. n=15 in all cases. *= p≤0.05, **= p≤0.01 and ***= p≤0.001 for 
AED effects. 
 
Figure 5. Effects of co-administration of CBDV and AEDs on pilocarpine-induced 
convulsions in rat 
The effects of CBDV co-administration with valproate (A-D) or phenobarbital (E-I) on 
pilocarpine induced convulsions: severity (A & E), mortality (B & F), the incidence of tonic-
clonic convulsions (C & G), onset latency (D & H) and (for CBDV+phenobarbital only) the 
proportion of animals that remained seizure-free. In D & H, onset latency is presented ± 
S.E.M. In A & E, median severity is represented by a thick horizontal line, the 25th & 75th 
percentiles by the box and maxima and minima are represented by "whiskers". Co-A
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administration of 200 mg kg-1 CBDV is represented by grey plots, CBDV vehicle by black. 
Significance of CBDV treatment is given in text. n=15 in all cases. *= p≤0.05, **= p≤0.01 
and ***= p≤0.001 for AED effects. 
 
Figure 6. Effects of CBDV on performance in the static beam and forelimb grip 
strength assays in rat and as an orally-administered anticonvulsant 
A&B: Static beam performance; including the pass rate (A) and foot slips (B). C: 
Performance in the grip strength assay. A, pass rate is represented as percentage; B&C, 
represented as mean ± S.E.M. n=20 for static beam data, 10 for grip strength. D Effect of 
orally administered 400 mg kg-1 CBDV on the severity of PTZ-induced seizures. A-C: n=20, 
D: n=15. *= p≤0.05, **= p≤0.01 and ***= p≤0.001 respectively. A-C: "V": CBDV vehicle, 
"S": valproate vehicle (saline).  
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TABLE 1 
Score PTZ-induced seizures Pilocarpine-induced seizures 
0 Normal behaviour Normal behavior 
1 Isolated myoclonic jerks Mouth clonus 
2 Atypical clonic seizure Unilateral forelimb clonus 
3 Fully developed bilateral forelimb clonus Bilateral forelimb clonus 
3.5 Forelimb clonus with tonic component 
and body twist N/A 
4 Tonic–clonic seizure with suppressed 
tonic phase* 
Bilateral forelimb clonus with rearing 
and falling 
4.5 N/A 
Tonic-clonic seizure with postural 
control retained 
5 Fully developed tonic–clonic seizure* Tonic-clonic seizure* 
Table 1. Seizure behaviour scoring scales for PTZ and pilocarpine-induced seizures. 
Seizure severity scoring scales are shown for each model although no equivalency of severity 
should be assumed between scales for different models. * indicates a loss of righting reflex. 
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TABLE 2 
60 min  
CBDV/vehicle 
treatment (I.P.) 
Time 
A 
AED treatment (I.P.) 
Time 
B 
Seizure 
induction and 
recording 
200 mg kg-1 
CBDV (n=60) 
Valproate (VPA) vehicle, 50, 
100, 250 mg kg-1 VPA (n=15 
each) 
CBDV 
vehicle (n=60) 
30 
min 
VPA vehicle, 50, 100, 250 mg 
kg-1 VPA (n=15 each) 
30 
min 
200 mg kg-1 
CBDV (n=60) 
Ethosuximide (ESM) vehicle, 
60, 120, 175mg kg-1 ESM 
(n=15 each) P
TZ
 
ex
pe
ri
m
en
ts
 
CBDV 
vehicle (n=60) 
30 
min 
ESM vehicle, 60, 120, 175mg 
kg-1 ESM (n=15 each) 
30 
min 
 
85mg kg-1 PTZ 
 
30 min recording 
200 mg kg-1 
CBDV (n=60) 
VPA vehicle, 62.5, 125, 250 
mg kg-1 VPA (n=15 each) 
CBDV 
vehicle (n=60) 
15 
min VPA vehicle, 62.5, 125, 250 
mg kg-1 VPA (n=15 each) 
45 
min 
200 mg kg-1 
CBDV (n=60) 
Phenobarbital (PB) vehicle, 10, 
20, 40 mg kg-1 PB 
(n=15 each) 
Pi
lo
ca
rp
in
e 
ex
pe
ri
m
en
ts
 
CBDV 
vehicle (n=60) 
15 
min PB vehicle, 10, 20, 40 mg kg-1 
PB 
(n=15 each) 
45 
min 
380 mg kg-1 
pilocarpine 
 
60 min recording 
Table 2. Experimental design and timecourse of co-administration experiments 
"Time A" column: time between CBDV/CBDV vehicle and AED administration. "Time B" 
column: time between AED/vehicle and convulsant. The duration of seizure recording is 
indicated in the final column. A
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